Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Puromycin

Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.

Product Specifications

CAS Number

[53-79-2]

Product Name Alternative

CL13900

UNSPSC

12352005

Hazard Statement

H302

Target

Antibiotic; Bacterial; Parasite

Type

Natural Products

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Puromycin.html

Purity

99.55

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 1 mg/mL (ultrasonic)

Smiles

OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O

Molecular Formula

C22H29N7O5

Molecular Weight

471.51

Precautions

H302

References & Citations

[1]Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92.|[2]Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28 (5) :1176-82.|[3]Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6 (4) :275-7.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Natural Products

Clinical Information

Launched

Isoform

Aminoglycoside

Citation 01

Acta Diabetol. 2025 Jul 2.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Acta Pharmacol Sin. 2025 May;46 (5) :1236-1249.|Adv Funct Mater. 2019, 1808556.|Adv Healthc Mater. 2025 Apr;14 (10) :e2404501.|Adv Sci (Weinh) . 2024 Dec 25:e2406822.|Adv Sci (Weinh) . 2025 Apr;12 (15) :e2413882.|Adv Sci (Weinh) . 2025 Jun 5:e06529.|Adv Tradit Med. 2025 Aug 8.|Biochem Pharmacol. 2017 Mar 15:128:12-25.|Biochem Pharmacol. 2026 Jan;243 (Pt 2) :117529.|Biochim Biophys Acta Mol Basis Dis. 2025 Oct;1871 (7) :167965.|Biol Direct. 2024 Nov 26;19 (1) :122.|bioRxiv. 2023 Jun 17.|bioRxiv. 2024 Sep 29:2024.09.26.615290.|bioRxiv. 2025 March 24.|bioRxiv. 2025 Nov 6.|BMC Biol. 2025 Feb 28;23 (1) :66.|Br J Cancer. 2025 Jul 28.|Cancer Cell Int. 2019 Jul 24:19:192.|Cancer Cell Int. 2025 Jun 9;25 (1) :207.|Cancer Commun (Lond) . 2025 Jun 20.|Cancer Immunol Res. 2023 Jul 5;11 (7) :875-894.|Cell Death Dis. 2025 Apr 11;16 (1) :274.|Cell Death Dis. 2025 Oct 6;16 (1) :696.|Cell Signal. 2019 Jun:58:119-130.|Commun Biol. 2025 Jul 29;8 (1) :1127.|Commun Biol. 2025 Nov 20;8 (1) :1626.|Development. 2024 Nov 1;151 (21) :dev202899.|Evid Based Complement Alternat Med. 2019 Mar 24:2019:1635837.|Genes Dis. 2025 Apr 1.|Hepatology. 2021 Apr;73 (4) :1327-1345.|Hum Cell. 2025 Oct 4;38 (6) :170.|Indian J Pharm Educ. 2024 Jun 21.|Int Immunopharmacol. 2025 Mar 26:150:114266.|Int J Biol Macromol. 2025 Jan 24:140310.|Int J Biol Macromol. 2025 Sep;321 (Pt 1) :145938.|Int J Biol Sci. 2024 Oct 14;20 (14) :5548-5575.|Int J Biol Sci. 2025 Jun 20;21 (9) :4215-4230.|Int J Oncol. 2020 Jul;57 (1) :161-170.|Int J Oral Sci. 2025 Feb 28;17 (1) :15.|J Cell Biol. 2025 Dec 1;224 (12) :e202412005.|J Cell Mol Med. 2019 Feb;23 (2) :954-966.|J Control Release. 2025 Jul 10:383:113814.|J Ethnopharmacol. 2025 Aug 18;353 (Pt B) :120435.|J Exp Clin Cancer Res. 2016 Nov 7;35 (1) :173. |J Exp Clin Cancer Res. 2025 Aug 19;44 (1) :245.|J Exp Clin Cancer Res. 2025 Mar 4;44 (1) :81.|J Extracell Vesicles. 2025 Aug;14 (8) :e70146.|J Extracell Vesicles. 2025 Sep;14 (9) :e70162.|J Hepatocell Carcinoma. 2024 Sep 18:11:1763-1775.|J Mol Histol. 2025 Sep 13;56 (5) :312.|J Pathol. 2025 Jul 21.|J Transl Med. 2024 Nov 22;22 (1) :1052.|Liver Res. 2025 Sep 22.|Microbiome. 2025 Jan 27;13 (1) :27.|Mol Biomed. 2025 Nov 27;6 (1) :122.|Mol Carcinog. 2025 Jan;64 (1) :57-71.|Mol Neurobiol. 2025 Jul;62 (7) :9290-9305.|Mol Neurobiol. 2025 Nov 14;63 (1) :41.|Nat Aging. 2025 Sep 10.|Nat Commun. 2024 Nov 6;15 (1) :9578.|Nat Commun. 2025 Jan 2;16 (1) :263.|Nat Commun. 2025 Jun 2;16 (1) :5101.|Nat Commun. 2025 Oct 10;16 (1) :9027.|Nat Metab. 2025 May;7 (5) :985-1003.|Nat Protoc. 2025 Oct 8.|NPJ Precis Oncol. 2025 May 3;9 (1) :127.|Onco Targets Ther. 2019 Jan 25:12:835-848.|Oncogene. 2024 Nov;43 (47) :3469-3482.|Oncogene. 2025 Oct 11.|Oncol Lett. 2025 Jan 15;29 (3) :143.|Oncol Rep. 2026 Jan;55 (1) :5.|Orphanet J Rare Dis. 2025 Aug 1;20 (1) :392.|Pharm Res. 2025 Aug;42 (8) :1315-1329.|Placenta. 2024 Dec:158:156-164.|PLoS One. 2017 Oct 10;12 (10) :e0185565.|Proc Natl Acad Sci U S A. 2025 Feb 25;122 (8) :e2424906122.|Purdue University. 2025.|R Soc Open Sci. 2018 Aug 29;5 (8) :172376.|Redox Biol. 2025 Aug 5:86:103806.|Reprod Biol Endocrinol. 2025 Sep 24;23 (1) :121.|Res Sq. 2024 Nov 07.|Research Square Print. 2025 May 28.|Respir Res. 2025 Apr 28;26 (1) :168.|Sci Adv. 2025 Feb 28;11 (9) :eadq2881.|Sci Immunol. 2025 Jun 27;10 (108) :eadn1630.|SSRN. 2025 Jan 24.|SSRN. 2025 Oct 9.|SSRN. 2025 Sep 16.|Theranostics. 2020 May 16;10 (14) :6483-6499. |Theranostics. 2021 Mar 5;11 (10) :5045-5060.|Toxicol Appl Pharmacol. 2019 Sep 1:378:114625.|Transl Res. 2023 Sep:259:62-71.|Vet Sci. 2025 Jan 13;12 (1) :52.|Virology. 2025 May:606:110504.|Viruses. 2024 Dec 18;16 (12) :1932.|World J Clin Oncol. 2025 Jun 24;16 (6) :106197.|World J Diabetes. 2025 Mar 15;16 (3) :101328.|World J Surg Oncol. 2025 Nov 14;23 (1) :434.|ACS Omega. 2025 Apr 7;10 (15) :15461-15470.|Acta Pharmacol Sin. 2023 Jul;44 (7) :1464-1474.|Adv Mater. 2023 Jan;35 (1) :e2206793.|Adv Sci (Weinh) . 2024 Apr;11 (16) :e2308531.|Adv Sci (Weinh) . 2024 Dec 25:e2407064.|Adv Sci (Weinh) . 2024 Dec;11 (46) :e2407967.|Adv Sci (Weinh) . 2024 Jun 26:e2404822.|Adv Sci (Weinh) . 2025 Apr;12 (13) :e2404961.|Adv Sci (Weinh) . 2025 Aug 22:e06225.|Adv Sci (Weinh) . 2025 Jul 23:e17248.|Adv Sci (Weinh) . 2025 Oct 27:e12966.|Aging (Albany NY) . 2021 Jun 8;13 (11) :14892-14909.|Aging. 2020 Sep 14;12 (17) :17122-17136.|Am J Cancer Res. 2023 May 15;13 (5) :1718-1743.|Am J Cancer Res. 2023 Sep 15;13 (9) :4222-4234.|Am J Transl Res. 2021 Apr 15;13 (4) :2331-2349.|Am J Transl Res. 2021 May 15;13 (5) :4360-4375.|Amino Acids. 2025 Aug 22;57 (1) :42.|Anal Biochem. 2021 Oct 15:631:114357.|Antioxid Redox Signal. 2023 Jan;38 (1-3) :115-136.|Antioxidants (Basel) . 2023 Aug 18;12 (8) :1634.|Arch Biochem Biophys. 2023 Jul 15:743:109642.|Autophagy. 2021 Dec;17 (12) :4083-4101.|Autophagy. 2024 Jul 26:1-17.|Autophagy. 2025 Jun;21 (6) :1192-1211.|Bioact Mater. 2021 Nov 12:13:149-160.|Biochem Biophys Res Commun. 2021 Nov 26:580:48-55.|Biochem Biophys Res Commun. 2022 Jan 1:586:34-41.|Biochem Biophys Res Commun. 2022 Oct 15:625:23-30.|Biochem Pharmacol. 2020 Apr;174:113776.|Biochem Pharmacol. 2024 Jul 10:116418.|Biochem Pharmacol. 2024 Jul 10:116422.|Biochem Pharmacol. 2024 May 9:225:116256.|Biochem Pharmacol. 2025 Aug 9;242 (Pt 2) :117222.|Biochim Biophys Acta Mol Basis Dis. 2024 Apr 20;1870 (5) :167195.|Biochim Biophys Acta Mol Basis Dis. 2024 Aug 5:167453.|Biochim Biophys Acta Mol Basis Dis. 2025 Jan 3:167650.|Biochim Biophys Acta Mol Cell Res. 2024 Jun 3:119768.|Biodes Manuf. 03 March 2022.|Biodes Manuf. 2022 Apr 18.|Biol Res. 2024 May 17;57 (1) :30.|Biomed Pharmacother. 2020 Jan;121:109578.|bioRxiv. 2023 Mar 31:2023.03.29.534783.|bioRxiv. 2023 Oct 4.|bioRxiv. 2024 August 30.|bioRxiv. 2024 Mar 29.|bioRxiv. 2025 April 10.|bioRxiv. 2025 Aug 17.|bioRxiv. 2025 Jun 21:2025.06.20.660750.|bioRxiv. April 11, 2022.|BMC Cancer. 2018 Feb 13;18 (1) :182. |Bone Res. 2025 Mar 3;13 (1) :30.|Bull Cancer. 2023 Apr;110 (4) :342-351.|Burns Trauma. 2025 Sep 18.|Cancer Commun (Lond) . 2023 Jan;43 (1) :123-149.|Cancer Immunol Res. 2023 May 3;11 (5) :600-613.|Cancer Invest. 2021 May;39 (5) :423-434.|Cancer Lett. 2020 Nov 1;492:162-173.|Cancer Lett. 2021 Jul 28:511:36-46.|Cancer Lett. 2021 Oct 10:518:266-277.|Cancer Lett. 2024 Jun 1:591:216848.|Cancer Lett. 2024 Mar 31:585:216674.|Cancer Lett. 2025 Oct 2:218073.|Cancer Manag Res. 2021 Nov 30;13:8915-8928.|Cancer Med. 2019 Oct;8 (13) :5903-5915.|Cancer Res. 2023 Jul 5;83 (13) :2187-2207.|Cancer Sci. 2024 Aug;115 (8) :2565-2577.|Cell Biol Toxicol. 2024 Aug 7;40 (1) :65.|Cell Commun Signal. 2022 Jun 15;20 (1) :87.|Cell Commun Signal. 2025 Nov 13;23 (1) :496.|Cell Death Dis. 2020 Dec 2;11 (12) :1032.|Cell Death Dis. 2021 Oct 14;12 (10) :944.|Cell Death Dis. 2021 Sep 9;12 (9) :842.|Cell Death Dis. 2022 Apr 18;13 (4) :360.|Cell Death Dis. 2023 Feb 11;14 (2) :107.|Cell Death Dis. 2023 Nov 25;14 (11) :765.|Cell Death Dis. 2023 Oct 6;14 (10) :653.|Cell Death Dis. 2025 Jan 16;16 (1) :23.|Cell Death Dis. 2025 Jun 17;16 (1) :452.|Cell Death Dis. 2019 Nov 21;10 (12) :879. |Cell Death Discov. 2021 Aug 30;7 (1) :226.|Cell Death Discov. 2021 May 1;7 (1) :89.|Cell Death Discov. 2022 Apr 23;8 (1) :222.|Cell Death Discov. 2022 Dec 16;8 (1) :493.|Cell Death Discov. 2022 Feb 22;8 (1) :77.|Cell Death Discov. 2022 Oct 28;8 (1) :432.|Cell Discov. 2025 Mar 11;11 (1) :22.|Cell Metab. 2025 Sep 2;37 (9) :1907-1925.e14.|Cell Metab. 2025 Sep 24:S1550-4131 (25) 00385-7.|Cell Mol Biol (Noisy-le-grand) . 2024 Jun 5;70 (6) :122-128.|Cell Mol Immunol. 2024 Jun;21 (6) :546-560.|Cell Rep Med. 2025 Jan 16:101922.|Cell Rep. 2024 Aug 22;43 (9) :114662.|Cell Rep. 2024 Dec 13;43 (12) :115060.|Cell Rep. 2024 Feb 27;43 (2) :113739.|Cell Rep. 2024 Mar 23;43 (4) :114003.|Cell Rep. 2025 Jan 18;44 (2) :115226.|Cell Signal. 2021 Mar:79:109878.|Cell Signal. 2025 Jan 3:111583.|Clin Cancer Res. 2025 Jul 8.|Clin Epigenetics. 2022 Dec 2;14 (1) :164.|Clin Transl Oncol. 2021 Sep;23 (9) :1942-1954.|Clin Transl Oncol. 2023 May;25 (5) :1425-1435.|Commun Biol. 2022 Aug 30;5 (1) :887.|Commun Biol. 2024 Dec 26;7 (1) :1701.|Commun Biol. 2025 Mar 26;8 (1) :496.|Comput Biol Med. 2024 Feb:169:107975.|Dig Liver Dis. 2023 Jul;55 (7) :967-981.|Dis Markers. 2022 Sep 23;2022:8402116.|DNA Cell Biol. 2022 Apr;41 (4) :447-455.|Drug Resist Updat. 2025 Apr 17:81:101246.|Electrophoresis. 2025 Sep 23.|EMBO Rep. 2021 Aug 4;22 (8) :e52205.|EMBO Rep. 2025 Sep 22.|Environ Health. 2025 Nov 28, XXXX (XXX) .|Environ Toxicol. 2023 Jun;38 (6) :1318-1331.|Environ Toxicol. 2024 Feb;39 (2) :803-814.|Exp Cell Res. 2023 Apr 11;427 (1) :113598.|Exp Cell Res. 2023 Jul 1;428 (1) :113613.|Exp Cell Res. 2024 Apr 16;438 (1) :114038.|Exp Mol Med. 2022 Jul;54 (7) :890-905.|Exp Mol Pathol. 2021 Dec:123:104704.|FASEB J. 2025 Jun 15;39 (11) :e70674.|Food Funct. 2024 Dec 9;15 (24) :11875-11887.|Front Biosci (Landmark Ed) . 2025 Apr 30;30 (5) :27094.|Front Oncol. 2021 Apr 21:11:669560.|Gene. 2024 Aug 22:931:148855.|Genes (Basel) . 2022 Sep 29;13 (10) :1760.|Heliyon. 2022 Dec 6;8 (12) :e12118.|Heliyon. 2023 Aug 9;9 (8) :e19034.|Heliyon. 2023 Nov 23;9 (12) :e22595.|Hum Cell. 2023 Sep;36 (5) :1755-1772.|Int Immunopharmacol. 2023 Sep:122:110616.|Int Immunopharmacol. 2024 Nov 16;143 (Pt 3) :113622.|Int Immunopharmacol. 2025 Aug 26:164:115417.|Int J Biol Macromol. 2023 Jun 30:241:124476.|Int J Biol Macromol. 2025 Dec;333 (Pt 2) :148750.|Int J Mol Sci. 2023 Sep 23;24 (19) :14476.|Int J Oncol. 2023 Apr;62 (4) :45.|Int J Oncol. 2024 Apr;64 (4) :45.|J Appl Toxicol. 2023 Oct;43 (10) :1421-1435.|J Biochem Mol Toxicol. 2025 Apr;39 (4) :e70210.|J Biol Chem. 2021 Jan-Jun:296:100276.|J Biol Chem. 2021 Jan-Jun:296:100413.|J Biol Chem. 2023 Mar;299 (3) :102961.|J Cancer. 2023 May 8;14 (8) :1309-1320.|J Cancer. 2024 Sep 9;15 (17) :5762-5772.|J Cell Mol Med. 2023 Apr;27 (8) :1045-1055.|J Ethnopharmacol. 2023 Aug 10:312:116446.|J Exp Clin Cancer Res. 2021 Nov 25;40 (1) :373.|J Exp Clin Cancer Res. 2022 Mar 28;41 (1) :111.|J Exp Clin Cancer Res. 2023 Nov 6;42 (1) :294.|J Exp Clin Cancer Res. 2023 Oct 3;42 (1) :258.|J Exp Clin Cancer Res. 2025 Mar 14;44 (1) :97.|J Exp Clin Cancer Res. 2025 Mar 19;44 (1) :99.|J Hematol Oncol. 2021 Jul 10;14 (1) :109.|J Nanobiotechnology. 2025 Nov 18;23 (1) :717.|J Transl Med. 2024 Jun 20;22 (1) :584.|J Transl Med. 2024 May 21;22 (1) :485.|J Virol. 2024 Jun 28:e0083024.|Life Sci. 2022 Mar 15:293:120320.|mBio. 2023 Dec 19;14 (6) :e0168823.|MedComm (2020) . 2024 May 31;5 (6) :e576.|Metabolism. 2025 Nov 4:175:156426.|Microbiol Res. 2025 May 14:298:128223.|Mol Cancer. 2024 May 6;23 (1) :90.|Mol Cancer. 2019 Aug 22;18 (1) :127. |Mol Carcinog. 2023 Sep;62 (9) :1338-1354.|Mol Carcinog. 2025 Jul 17.|Mol Cell Biochem. 2021 Jun;476 (6) :2503-2512.|Mol Cell. 2023 Dec 21;83 (24) :4494-4508.e6.|Mol Cell. 2023 Dec 7;83 (23) :4370-4385.e9.|Mol Cell. 2024 Aug 1:S1097-2765 (24) 00593-8.|Mol Pharm. 2024 Jul 1;21 (7) :3447-3458.|Mol Ther Nucleic Acids. 2025 May 14;36 (2) :102560.|Molecules. 2023 Jan 22;28 (3) :1103.|Nat Commun. 2019 Dec 2;10 (1) :5492. |Nat Commun. 2022 Mar 10;13 (1) :1248.|Nat Commun. 2025 Aug 7;16 (1) :7309.|Nat Commun. 2025 Feb 27;16 (1) :2039.|Nat Commun. 2025 Mar 14;16 (1) :2511.|Nat Commun. 2025 Sep 11;16 (1) :8263.|Neural Regen Res. 2025 Apr 29.|Neuro Oncol. 2022 Dec 1;24 (12) :2107-2120.|NPJ Precis Oncol. 2024 Mar 1;8 (1) :58.|Nucleic Acids Res. 2024 Apr 12;52 (6) :3291-3309.|Oncogene. 2022 Feb;41 (6) :770-781.|Oncogene. 2023 Sep;42 (39) :2878-2891.|Oncol Lett. 2023 Dec 18;27 (2) :59.|Oncol Rep. 2021 Feb;45 (2) :523-534.|Oncol Rep. 2023 Aug;50 (2) :148.|Oncotargets Ther. 2020 Sep 30;13:9701-9719.|PeerJ. 2022 Jun 6:10:e13535.|Phytomedicine. 2023 Jun:114:154769.|Poult Sci. 2023 Oct;102 (10) :102864.|Reprod Biomed Online. 2023 Nov;47 (5) :103253.|Research (Wash D C) . 2022 Aug 3:2022:9832128.|Research (Wash D C) . 2025 Mar 18:8:0635.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Nov 25.|Research Square Preprint. 2023 Sep 27.|Research Square Print. 2022 Aug.|Research Square Print. 2023 Mar 15.|Sci Adv. 2025 Jun 27;11 (26) :eadq9643.|Sci Bull. 2025 Nov 25:S2095-9273 (25) 01198-3.|Sci China Life Sci. 2025 Jan;68 (1) :204-218.|Sci Rep. 2022 Nov 5;12 (1) :18809.|Sci Rep. 2025 Apr 30;15 (1) :15207.|Science. 2024 Feb 2;383 (6682) :eadh4859.|Signal Transduct Target Ther. 2022 Feb 28;7 (1) :54.|Signal Transduct Target Ther. 2024 Dec 18;9 (1) :352.|SSRN. 2021 Jun.|STAR Protoc. 2022 Apr 13;3 (2) :101296.|STAR Protoc. 2022 Nov 2;3 (4) :101808.|Stem Cell Res Ther. 2024 Dec 2;15 (1) :458.|Stem Cell Rev Rep. 2023 May;19 (4) :1019-1033.|Stem Cells Int. 2020 Aug 29:2020:8860185.|Thorac Cancer. 2024 May 8.|Transl Oncol. 2024 Jul 3:47:101950.|Transl Oncol. 2024 Jul:45:101958.|University of Bonn. 2025 Feb.|Vet Microbiol. 2023 Sep:284:109823.|Virology. 2025 Jan 7:603:110397.|Virus Res. 2023 Apr 15:328:199086.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

ZBTB10 CRISPRa sgRNA lentivector (set of three targets)(Rat)
50684126 3x 1.0µg DNA

ZBTB10 CRISPRa sgRNA lentivector (set of three targets)(Rat)

Ask
View Details
Lentiviral mouse Kyat1 shRNA (UAS) - Lentiviral mouse Kyat1 shRNA (UAS) (100)
GTR15281118 1 Vial

Lentiviral mouse Kyat1 shRNA (UAS) - Lentiviral mouse Kyat1 shRNA (UAS) (100)

Ask
View Details
Mouse monoclonal HADH Antibody (OTI3D12)
NBP2-45931 0.1 mL

Mouse monoclonal HADH Antibody (OTI3D12)

Ask
View Details
Mouse anti-FluB nucleoprotein mAb (J44)
A09F12-J44 1 Each

Mouse anti-FluB nucleoprotein mAb (J44)

Ask
View Details
Human Immunoglobulin M (IgM) AssayMax™ ELISA Kit
EI7301-1 96 Well

Human Immunoglobulin M (IgM) AssayMax™ ELISA Kit

Ask
View Details
4- (3-Phenothiazin-10-ylpropyl) -1-piperazineethanol
161042 100 mg

4- (3-Phenothiazin-10-ylpropyl) -1-piperazineethanol

Ask
View Details